Octopus AIM VCT plc

Data as at 31 May 2022



Octopus AIM VCT plc is a Venture Capital Trust (VCT) which aims to provide shareholders with attractive tax-free dividends and long-term capital appreciation by investing in a diverse portfolio of predominantly AIM-quoted companies.

Risk is spread by investing in a number of different businesses across a range of activities.

Key Facts

Net Assets	£152.6m
Market Cap	£145.5m
Shares Issued	159.8m
Launch Date	1998
Benchmark	FTSE AIM All-Share TR
Number of Holdings	90
Year End	28 February

Current Price

NAV per share* 95.3p Share price (mid) 91.0p

*NAV reported weekly.

Share buybacks: the VCT can buy back up to 10% of the share capital annually at a 5% discount to NAV, subject to Board approval.

About the Team

The Octopus Quoted Companies team has a combined experience of more than 100 years. The team, which includes Richard Power, Kate Tidbury, Chris McVey, Edward Griffiths, Stephen Henderson, Mark Symington, Dominic Weller, Jessica Sweeney, Freda Isingoma and Charles Lucas, manage over £2.6 billion in quoted companies, and are also responsible for the Octopus AIM Inheritance Tax Service, FP Octopus UK Micro Cap Growth Fund, FP Octopus UK Multi Cap Income Fund and FP Octopus UK Future Generations Fund.















					Calendar Year		
	YTD	3 years	5 years	2021	2020	2019	
Octopus AIM VCT NAV TR	-21.40	12.54	4.10	8.60	22.39	10.75	
Octopus AIM VCT Share Price TR	-17.65	12.23	7.32	11.78	17.50	10.31	
■ FTSE AIM All-Share TR	-19.43	4.83	4.12	6.12	21.75	13.26	
■ FTSE All-Share TR	1.50	18.44	22.17	18.32	-9.82	19.17	

Discrete yearly performance (%)

Year to 31 May	2022	2021	2020	2019	2018
Octopus AIM VCT NAV TR	-22.50	49.41	-2.66	-10.57	4.02
Octopus AIM VCT Share Price TR	-22.25	51.84	-4.93	-9.95	6.19
FTSE AIM All-Share TR	-21.50	44.64	-7.68	-10.14	10.54
FTSE All-Share TR	8.27	23.13	-11.16	-3.17	6.53

Source: Lipper and Octopus Investments. VCT performance is shown as a simple return comparison between the NAV at the beginning of the period and the NAV, plus any dividends paid out, at the end of the period. VCT share price performance shown includes reinvested dividends. NAV is stated after deduction of fees.

Key Risks

- Your capital is at risk and you may not get back the full amount invested.
- Tax treatment depends on individual circumstances and may be subject to change.
- Investments quoted on AIM are likely to fall and rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
- The availability of tax reliefs also depends on the investee companies maintaining their qualifying status.
- Past performance is not a reliable indicator of future returns.









THINKER



5-Year Dividend History

Pay Date	Туре	Dividend
04 Aug 2017	Final	3.00p
19 Jan 2018	Interim	2.50p
20 Jul 2018	Final	3.00p
18 Jan 2019	Interim	2.50p
02 Aug 2019	Final	3.00p
17 Jan 2020	Special	3.50p
17 Jan 2020	Interim	2.50p
07 Aug 2020	Final	3.00p
15 Jan 2021	Interim	2.50p
13 Aug 2021	Special	2.50p
13 Aug 2021	Final	3.50p
14 Jan 2022	Interim	2.50p

The Board targets a minimum dividend of 2.5p each half year with the final adjusted annually, based on the year-end share price, so that shareholders receive either 5p per annum or a 5% yield, whichever is greater at the time.

Directors

Neal Ransome (Chairman) Joanne Parfrey Stephen Hazell-Smith Andrew Boteler

Fees & Codes

Management Fee Total Ongoing Charges*	2.00% 1.70%		
ISIN Code	GB0034202076		
Sedol Code	3420207		
Ticker (LSE)	OOA		

^{*}Calculated as at 28 February 2021

Monthly Commentary

During May, the Net Asset Value (NAV) of the Octopus AIM VCT fell by 5.46%. This compares to a 4.42% decrease in the FTSE AIM All Share and a 0.69% increase in the FTSE All Share, both on a total return

Equity market sentiment remained under pressure during the month. Lingering concerns over the inflationary environment, further interest rate rises, the terrible conflict in Ukraine, and continued lockdown conditions in China combined to keep investor appetite for risk low. However, as we have commented on in previous updates this year, the vast majority of company-specific news-flow remains positive, with management teams continuing to provide optimistic but cautious outlooks for the remainder of the year. Market volatility and depressed share prices are likely to persist in the coming months, but we remain confident that valuations will begin to return towards more normal levels once sentiment improves and companies meet or exceed the muted market expectations for earnings. Positive updates included Judges Scientific, who have acquired geological services provider Geotek for up to £80 million in cash and shares. It looks an excellent addition to the Group and is expected to be earnings enhancing in the current year. Specialist instrumentation business, SDI Group, provided a very good trading update for the year to 30 April 2022. Strong customer demand meant that revenues, profits, and cash flow exceeded market expectations for the year. Management is cautiously optimistic that FY23 will be a record year for the group. Cell therapy technology provider, **Maxcyte**, delivered a very good quarter one trading update. It outlined 25% year-on-year revenue growth and increased guidance. However, its shares have been weighed down by negative investor sentiment towards the biotech sector. Automotive retailer, Vertu Motors, delivered an extraordinary set of results for the year to 28 February 2022, in which adjusted profit before tax increased more than threefold to £80.7 million. Net cash was ahead of market expectations at £16.2 million. The exceptionally buoyant market in second hand cars has been lucrative for the Group, though this situation is unlikely to persist over the course of this year as consumer demand comes under pressure. Accounts Payable software and service provider, **Glantus Holdings**, provided a solid set of maiden figures since its AlM IPO in May last year. The business delivered revenue growth of 27% in the year to 31 December 2021, and current trading is in line with market expectations.

Major detractors from performance over the month included solid state battery developer, **Ilika**. It provided a trading update for the year to 30 April 2022, which was in line with market expectations. However, the company is behind production schedule in its miniaturised battery, Stereax, which means that commercialisation in that product line is likely to be delayed. However, scale-up in its larger format battery, Goliath, remains on track. Shares in digital marketing services provider, Next Fifteen Communications, fell despite providing a very good update for its first quarter. Revenues were up 37% on an organic basis. Other detractors included Breedon Group and Ergomed, whose share prices retreated over the month despite providing no updates.

Portfolio Analysis

Top Ten Equity Holdings (%)		Top Ten Sectors (%)	
FP Octopus UK Micro Cap Growth	5.4	Software & Computer Services	13.6
Ergomed plc	5.3	Pharmaceuticals & Biotechnology	11.4
FP Octopus UK Multi Cap Income	4.5	Unit Trusts	10.3
Learning Technologies Group plc	4.0	Support Services	6.8
Popsa	3.5	Unquoted Investment	6.3
Breedon Group plc	3.3	Energy	5.0
GB Group plc	3.0	Specialty & Other Finance	4.8
Judges Scientific plc	2.6	Health	4.5
Libertine Holdings plc	2.5	Electronic & Electrical	4.2
Hasgrove plc	2.5	General Retailers	3.8
Total	36.6	Total	70.7

Glossary

Index

A representative portfolio of securities created to represent a particular market or a portion of it.

Net Asset Value (NAV)

The price-per-share of a fund or other investment. The per-share amount of the fund is based on the total value of all the securities in its portfolio, any liabilities the fund has and the number of fund shares outstanding

Total Return (TR)

The gain or loss derived from an investment over a specified period of time. This figure includes interest, capital gains, dividends, and income distributions realised over that time period.

Important Information

Personal opinions may change and should not be seen as advice or a recommendation. We do not offer investment or tax advice. We recommend investors seek professional advice before deciding to invest. Regarding VCTs, this advertisement is not a prospectus and you should only subscribe for shares on the basis of information contained in the prospectus and the Key Information Document. For other investments, investors should read the product brochure before deciding to invest. These documents are available at octopus investments.com. Issued by Octopus Investments Limited, which is authorised and regulated by the Financial Conduct Authority. Registered office: 33 Holborn, London, EC1N 2HT. Registered in England and Wales No. 03942880. We record telephone calls. CAM012108. Issued: June 2022.